Genentech Slaps Down Biosimilar Imports: Patents vs. Patients?
Published Date: 3/4/2026
Notice
Summary
The U.S. International Trade Commission got a complaint from Genentech about certain pertuzumab biosimilars being imported and sold in the U.S. They want to stop these products because of patent issues. The Commission is asking the public to share their thoughts on how this might affect everyone, with decisions and possible actions happening soon, including a 60-day review period.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Genentech Seeks Import Ban and Orders
Genentech filed a complaint on February 27, 2026 alleging that certain pertuzumab biosimilars are unlawfully imported and sold in the U.S. The company asks the Commission for a limited exclusion order, cease and desist orders, and for a bond to be imposed on the allegedly infringing articles during the 60-day Presidential review period under 19 U.S.C. 1337(j).
Public Comment Window Is Short and Electronic
The Commission invites public comments on public interest issues and requires written submissions to be filed no later than close of business eight calendar days after this notice's publication; complainant may reply within three calendar days. All filings must be made electronically through the Commission's Electronic Document Information System (EDIS), submissions are limited to five (5) pages, and no paper filings will be accepted until further notice (Docket No. 3890).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16905, Certain Transformers and Components Thereof; Notice of Institution of Investigation
A company called Ayr Energy says some transformers and their parts imported into the U.S. are using stolen secrets and fake branding, which could hurt American businesses. The U.S. International Trade Commission is now investigating and might stop these products from being sold here. This could lead to new rules and orders soon, affecting companies selling these transformers and possibly changing what’s on store shelves.
2026-16848, Silicon Metal From Australia and Norway; Determinations
2026-16816, Hand Trucks and Certain Parts Thereof From China; Determination
2026-16811, Certain Ink Cartridges and Components Thereof II; Notice of a Commission Determination Finding a Violation Under Section 337; Issuance of a General Exclusion Order and Cease and Desist Orders; Termination of the Investigation
Notice is hereby given that the U.S. International Trade Commission has determined to find a violation under section 337 of the Tariff Act of 1930, as amended, and to issue a general exclusion order ("GEO") prohibiting the importation of products that infringe claims 1 and 7 of each of the following patents: U.S. Patent Nos. 8,764,172 ("the '172 patent"); 9,370,934 ("the '934 patent"); 11,535,038 ("the '038 patent"); 12,240,248 ("the '248 patent"); and 12,240,249 ("the '249 patent"); and cease and desist orders ("CDOs") against respondents Mountain Peak, Inc. and Straightouttaink, LP. The investigation is terminated.
2026-16667, Certain Mobile Electronic Devices; Notice of Institution of Investigation
Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on July 10, 2026, under section 337 of the Tariff Act of 1930, as amended, on behalf of Maxell, Ltd. of Kyoto, Japan. An amended complaint was filed on July 24, 2026. The amended complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain mobile electronic devices by reason of the infringement of certain claims of U.S. Patent No. 10,812,646 ("the '646 patent"); U.S. Patent No. 12,513,408 ("the '408 patent"); U.S. Patent No. 12,061,760 ("the '760 patent"); U.S. Patent No. 12,418,692 ("the '692 patent"); U.S. Patent No. 12,185,211 ("the '211 patent"); and U.S. Patent No. 12,647,935 ("the '935 patent"). The amended complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The amended complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.
2026-16581, Carbazole Violet Pigment 23 From China and India; Termination of Five-Year Reviews
The Commission instituted the subject five-year reviews on May 1, 2026 to determine whether revocation of the countervailing duty order on carbazole violet pigment 23 from India and the antidumping duty orders on carbazole violet pigment 23 from China and India would be likely to lead to continuation or recurrence of material injury. On August 7, 2026, the Department of Commerce published notice in the Federal Register that it was revoking the orders applicable August 7, 2026, because no domestic interested party filed a timely notice of intent to participate. Accordingly, the subject reviews are terminated.
Previous / Next Documents
Previous: 2026-04235, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension: Rule 204-2
The SEC is asking to keep the current rules that require investment advisers to keep important business records for at least five years. This affects all SEC-registered investment advisers, who spend a lot of time (about 185 hours each) on this paperwork. The SEC wants to extend this rule without changes and invites public comments by April 6, 2026.
Next: 2026-04237, Board of Scientific Counselors, National Center for Injury Prevention and Control; Notice of Charter Renewal
The CDC just renewed the Board of Scientific Counselors for the National Center for Injury Prevention and Control’s charter for two more years, keeping their important work going through January 13, 2028. This means the board will keep advising on injury prevention strategies that affect public health, with no new costs announced. The renewal ensures the board stays active and ready to tackle injury-related challenges ahead.